

Un-audited Financial Results for the Quarter ended 31.12.2010 (₹ in Lacs)

S No.	PARTICULARS	Quarter ended 31.12.2010	Quarter ended 31.12.2009	9 Months Ended 31.12.2010	9 Months Ended 31.12.2009	Year Ended 31.3.2010
		Un-audited	Un-audited	Un-audited	Un-audited	Audited
1.	Gross Sales/Income from Operations Less : Excise Duty Net Sales / Income from Operations Other Operating Income Total Operating Income	33786.46 1743.21 32043.25 236.82 32280.07	25486.20 1281.05 24205.15 75.00 24280.15	75932.12 4191.48 71740.64 445.54 72186.18	63919.20 3506.24 60412.96 210.00 60622.96	88582.17 4002.26 84579.91 409.59 84989.50
2.	Expenditure a. (Increase)/decrease in stock in trade b. Consumption of Raw Material c. Employees Cost d. Depreciation e. Other Expenditure Total Expenditure	(803.90) 22817.12 1090.45 1164.31 2341.95 26609.93	104.78 16016.80 820.44 1013.71 1813.95 19769.68	(2492.08) 49044.53 2868.53 3435.50 6011.18 58867.66	843.53 37169.63 2395.36 2928.73 5268.62 48605.87	939.51 53491.67 3187.70 3874.64 7457.01 68950.53
3.	Profit from Operations before Other Income, Interest & Exceptional Items (1-2)	5670.14	4510.47	13318.52	12017.09	16038.97
4.	Other Income	12.53	57.64	18.24	208.05	1485.73
5.	Profit before Interest & Exceptional Items (3+4)	5682.67	4568.11	13336.76	12225.14	17524.70
6.	Interest	1567.30	1353.41	4185.67	4056.33	6028.44
7.	Profit after Interest but before Exceptional Items (5-6)	4115.37	3214.70	9151.09	8168.81	11496.26
8.	Exceptional Items	0.00	0.00	0.00	0.00	0.00
9.	Profit from ordinary activities before tax (7+8)	4115.37	3214.70	9151.09	8168.81	11496.26
10.	Tax Expenses	1093.85	642.82	2146.37	1633.45	2298.82
11.	Net Profit from ordinary activities after tax (9-10)	3021.52	2571.88	7004.72	6535.36	9197.44
12.	Extraordinary Item (net of tax expense)	0.00	0.00	0.00	0.00	0.00
13.	Net Profit for the period (11-12)	3021.52	2571.88	7004.72	6535.36	9197.44
14.	Paid up Equity Share Capital (Face Value per share : ₹ 1/-)	2242.61	1522.61	2242.61	1522.61	2242.61
15.	Reserves excluding Revaluation Reserves					59855.37
16.	Earnings per Share (EPS) Basic EPS before Extraordinary items Diluted EPS before Extraordinary items Basic EPS after Extraordinary items Diluted EPS after Extraordinary items	1.35 1.07 1.35 1.07	1.69 1.23 1.69 1.23	3.12 2.49 3.12 2.49	4.29 3.12 4.29 3.12	5.81 4.28 5.81 4.28
17.	Public Shareholding - Number of Shares - Percentage of Shareholding	125246970 55.85	54119330 35.54	125246970 55.85	54119330 35.54	126119330 56.24
18.	Promoters and Promoter Group Shareholding a) Pledged/Encumbered - Number of Shares - Percentage of Shares (as a % of the total shareholding of promoter and promoter group) - Percentage of Shares (as a % of the total share capital of the company) b) Non-encumbered - Number of Shares - Percentage of Shares (as a % of the total shareholding of promoter and promoter group) - Percentage of Shares (as a % of the total share capital of the company)	0 0.00 0.00 99014000 100.00 44.15	0 0.00 0.00 98141640 100.00 64.46	0 0.00 0.00 99014000 100.00 44.15	0 0.00 0.00 98141640 100.00 64.46	0 0.00 0.00 98141640 100.00 43.76

Notes :

- During the quarter under review, we have made 7 DMF filings.
- During the quarter under review, 2 International Patents have been filed by the company
- The above financial results were reviewed by Audit Committee on 14.01.11 and approved by the Board in its meeting held on even date i.e. 14.01.11 and further limited reviewed by the Statutory Auditors of the Company
- The above financial results are on stand alone basis.
- The company is exclusively in the pharmaceutical business segment.
- The Company has allotted 26,000,000 equity shares on preferential basis on 20.02.2010 to non-promoters and 46,000,000 equity shares underlying Global Depository Receipts (GDRs) on 26.02.2010. After said allotments, the paid up equity capital of the company stands increased from ₹ 152,260,970/- to ₹ 224,260,970/- comprising of 224,260,970 equity shares of ₹ 1/- each. This is the reason of decrease in the %age of holding of the promoters, increase in the public shareholding and decrease in EPS.
- Gross Sales and Consumption of Raw Material figures for 2009-10 - Q3 and 9 months ended 31.12.2009 have been restated being net of Inter Unit Sales of ₹ 1773 lacs & ₹ 10120 lacs respectively so as to make it comparable with current period figures.
- Tax Expense Figures for 2009-10- Q3 and 9 months ended 31.12.2009 have been restated after providing for proportionate tax of ₹ 642.82 lacs & ₹ 1633.45 lacs respectively, so as to make it comparable with current period figures. The Tax expense for the year 2009-10 was provided in the audited financial results. Accordingly, previous years Q3 and 9 months ended 31.12.09 EPS has also been restated.
- Status of Complaints:

a) Pending at the beginning of Quarter - Nil	b) Received During the Quarter - 6
c) Disposed Off During the Quarter - 6	d) Pending at the end of Quarter - Nil

**By Order of the Board of Directors
of Nectar Lifesciences Limited**

**Sd/-
(Dinesh Dua)**

Chief Executive Officer & Director

**Dated : 14.01.2011
Place : Chandigarh**